U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07183748) titled 'Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression' on June 15.
Brief Summary: Objective:
To assess the safety and efficacy of a six-week microdosing regimen of psilocybin combined with short-term, experience-based psychotherapy in patients with treatment-resistant depression who have not responded to previous pharmacological or long-term psychological interventions.
Hypothesis:
Compared to baseline, the group that begins with psilocybin will exhibit a more rapid reduction in depressive symptoms after six weeks, compared to the group that begins with placebo and receives only psychotherapy. Following th...